Advancing Neoadjuvant Therapies: Oncolytic Immunotherapy and Nivolumab in MIBC

Roger Li, MD, speaks with GU Oncology Now about his recent research on oncolytic immunotherapy with nivolumab for MIBC, published in the journal Nature. For the study, Dr. Li examined the combination of oncolytic immunotherapy and immune checkpoint blockade for treating bladder cancer. This innovative neoadjuvant regimen targets micrometastatic disease in patients with both non-muscle invasive and muscle-invasive bladder cancer, showing efficacy on par with cisplatin-based chemotherapy.

Dr. Li discusses the role of key biomarkers, including tumor mutational burden and E2F activity, in predicting treatment response. He also explores surprising findings regarding PD-L1 status, revealing its unexpected implications for immune checkpoint therapy. The discussion highlights the significance of tertiary lymphoid structures and their potential to enhance humoral anti-tumor response.

#BladderCancer #OncolyticImmunotherapy #CancerResearch #ImmuneCheckpointBlockade #TertiaryLymphoidStructures